Skip to main content
. Author manuscript; available in PMC: 2014 Sep 19.
Published in final edited form as: Cochrane Database Syst Rev. 2011 Jan 19;(1):CD006626. doi: 10.1002/14651858.CD006626.pub2
Methods Allocation: random, no further details.
Blindness: double, no further details.
Duration: 6 weeks.
Design: parallel.
Participants Diagnosis: (DSM-IV) schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder or shared psychotic disorder.
N = 36.
Age: 65 years or more.
Sex: not described.
Location: not described.
Setting: not described.
History: duration ill, age at onset: not described.
Excluded: conditions such as: not described.
Interventions
  1. Amisulpride: flexible dose. Allowed dose range: 100-400 mg/day. Mean dose: n.i. N = 24

  2. Risperidone: flexible dose. Allowed dose range: 1-4 mg/day. Mean dose: n.i. N = 12

Outcomes Leaving the study early: adverse events.
Cognitive functioning: MMSE.
Adverse effects: open interviews.
Unable to use:
Mental state, PANSS total score, BPRS total score: no usable data.
Cardiac effects (QTc), laboratory tests: no data.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk Random, no further details.
Allocation concealment? Unclear risk No further details.
Blinding?
subjective outcomes
Unclear risk Double, no further details. Whether blinding was successful has not been examined, but both compounds differ in side effects. This may be a problem for blinding
Blinding?
objective outcomes
Low risk Objective outcomes such as laboratory measures or death are unlikely to have been much affected by problems of blinding
Incomplete outcome data addressed?
All outcomes
High risk Numbers of participants leaving the study early were only reported for the category “due to adverse effects”. The statistical method used to account for incomplete data was not described
Free of selective reporting? High risk The study is only available as an abstract. The data for primary outcomes were either not available or only available in percentage change without a standard deviation
Free of other bias? High risk The study was sponsored by the manufacturer of amisulpride. Whether there was a baseline imbalance could not be judged due to insufficient data